EchoIQ Limited

EchoIQ Limited

0.22
USD
-0.14
(-39.00%)
-0.02EPS
596.34MMarket Cap
Mar 04Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
- -
- -
- -
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.1
-0.2
-0.31
-0.45
-0.04
-0.01
-0.01
-0.01
-0.01
-0.02
-0.01
- -
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.36
0.24
0.01
0.02
- -
-0.01
0.01
0.02
0.02
0.02
0.01
- -
0.02
Tangible Book Value per Share
0.36
0.24
0.01
0.02
- -
-0.01
0.01
0.01
- -
- -
- -
- -
0.01
Basic Weighted Avg Shares
5
8
10
32
36
70
225
294
393
448
455
567
653
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
1
1
1
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
-1,360.36
-18,146.68
-43.55
-382.89
-318.92
-2,489.23
-7,150.58
-14,834.37
- -
-21,573.91
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
- -
1
Net Income, GAAP
-1
-2
-3
-14
-2
-1
-3
-3
-6
-8
-5
- -
-19
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-9,861.54
-10,505.43
-63.94
-400.46
-303.1
-2,259.45
-7,270.29
-12,155.38
- -
-20,180.43
Working Capital
- -
- -
- -
1
- -
-1
2
3
- -
1
- -
- -
7
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
3
2
- -
- -
- -
-1
3
9
8
7
7
- -
12
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-24.63
-72.45
-274.39
-5,582.94
- -
- -
- -
-47.87
-66.13
-102.17
-76.17
- -
- -

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
- -
2026
- -
- -
-0.03

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Dustin Haines
Full Time Employees
220
Sector
Non-energy minerals
Industry
Other metals/Minerals
Address
66 Clarence Street Claremont NSW Australia 2000
IPO Date
Dec 17, 2010
Website
echoiq.ai
Business
Echo IQ Limited is a medical technology company specializing in artificial intelligence solutions for cardiovascular diagnostics, operating from its base in Sydney, Australia. The company develops the advanced EchoSolv™ platform, which employs AI-driven analysis of echocardiographic data to significantly improve the identification and risk stratification of structural heart conditions such as aortic stenosis, diastolic dysfunction, and heart failure. This innovative technology assists medical professionals in making more precise and timely decisions for improved patient care. Echo IQ serves a broad range of healthcare providers, including physicians, hospitals, and health systems across Australia and the United States. The company’s revenue model is primarily software-as-a-service, incorporating per-scan payments and strategic licensing agreements. Key recent developments include securing FDA clearance for its EchoSolv-AS product in October 2024, enabling wider commercialization in the US market, and a substantial A$7.1 million institutional placement in September 2024 to support ongoing expansion and product development. Echo IQ has also forged significant partnerships with US healthcare technology providers like ScImage, MedAxiom, and SARC MedIQ to integrate its AI solutions across extensive cardiology networks. The company leverages exclusive access to a vast, de-identified cardiac data repository, critical for training its highly accurate AI algorithms that have demonstrated superior detection rates for serious heart conditions in clinical studies.

Company News

  • Echo IQ to Present at the Life Sciences Virtual Investor Forum on 11th December

  • Echo IQ to Participate in the Piper Sandler 37th Annual Healthcare Conference